CBPO  China Biologic Products Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-2.595 (-2.134%)

Growth Price

Overvalued by 66.60%

Stability Price

Overvalued by 81.40%

Company Metrics

  • P/E 35.598
  • P/S 10.374
  • P/B 7.787
  • EPS 3.343
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / 0%
  • Avg. Vol. 247,584.00
  • Shares 26.55M
  • Market Cap. 3.16B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


China Biologic Products Inc versus Ionis Pharmaceuticals Inc Head to Head Compare
CML News - Jul 22, 2016
China Biologic Products Inc has a substantially higher fundamental rating then Ionis Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Is China Biologic Products Inc's Fuel Running Low? The Stock Just Declined Again
Press Telegraph - 11 hours ago
The stock of China Biologic Products Inc (NASDAQ:CBPO) is a huge mover today! About 163,826 shares traded hands. China Biologic Products Inc (NASDAQ:CBPO) has declined 9.33% since December 22, 2015 and is downtrending. It has underperformed ...
New Broker Ratings For China Biologic Products, Inc. (NASDAQ:CBPO) - FTSE News
China Biologic Products, Inc. Stock Momentum at Critical Inflection Point
CML News - Jul 7, 2016
This is a momentum stock rating analysis for China Biologic Products, Inc. (NASDAQ:CBPO) . The company has a three bull momentum rating which indicates an inflection point.
China Biologic Products Inc Realized Volatility Hits Extremely Low Level
CML News - Jul 14, 2016
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for China Biologic Products Inc (NASDAQ:CBPO) . We examine the little used gem of daily stock volatilty over a ...
China Biologic Products Inc. (CBPO) Given "Buy" Rating at Jefferies Group
Community Financial News - Jul 22, 2016
China Biologic Products Inc. (NASDAQ:CBPO)'s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Group in a research note issued on Friday.
Investor Watch: Earnings and Street Rating Review for China Biologic Products ...
Engelwood Daily - Jul 27, 2016
Investors and analysts will be waiting to see if the company hits or misses earnings projections after the next earnings report. China Biologic Products, Inc. (NASDAQ:CBPO) is scheduled to next post quarterly results on or around 2016-08-04. The ...
Stock Warming Up This Summer: China Biologic Products, Inc. (NASDAQ:CBPO)
TGP - 14 hours ago
Investors holding shares of China Biologic Products, Inc. (NASDAQ:CBPO) have been treated this week to nice gains as shares are up 10.74% over the past five trading days.
Cutler Group Lp buys $6963821 stake in China Biologic Products Inc (CBPO)
Trade Calls - Jul 19, 2016
China Biologic Products Inc (CBPO) : Cutler Group Lp scooped up 52,798 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment ...
China Biologic Products Inc. (CBPO) Shares Sold by Renaissance Technologies LLC
Community Financial News - Jul 17, 2016
China Biologic Products logo Renaissance Technologies LLC decreased its stake in China Biologic Products Inc. (NASDAQ:CBPO) by 2.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Next Weeks Broker Price Targets For China Biologic Products, Inc. (NASDAQ:CBPO) - Fiscal Standard
Strong Sell Calls For China Biologic Products, Inc. (NASDAQ:CBPO) At 0 - Investor Newswire
Credit Suisse Downgrades China Biologic Products To Neutral
Benzinga - Mar 1, 2016
Credit Suisse's Iris Wang downgraded the rating on China Biologic Products Inc (NASDAQ: CBPO) to Neutral, while raising the price target to HK$129.